Key Takeaways
- Alnylam and City Therapeutics founder John Maraganore was a featured speaker at Biotech CEO & Investor, and reflected on lessons learned in his career.
- While the political environment and capital markets remain tumultuous, he said the industry remains resilient.
- A new US administration could present opportunities to modernize the FDA, he added.
Biotech leader John Maraganore has had a respected career in the industry, having built Alnylam Pharmaceuticals over 19 years into the leading RNAi therapeutics company in the world with five marketed RNAi medicines
Maraganore stepped down as CEO of Alnylam in 2021, with the company having a $25bn valuation, paving the way for his successor Yvonne Greenstreet. He has since embarked on a new corporate venture, launching the RNAi-based therapeutics company City Therapeutics with a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?